Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project
- Supplementary File 1:
ZIP-Document (ZIP, 154 KiB)
Polewska, K.; Tylicki, P.; Biedunkiewicz, B.; Rucińska, A.; Szydłowska, A.; Kubanek, A.; Rosenberg, I.; Rodak, S.; Ślizień, W.; Renke, M.; Dębska-Ślizień, A.; Tylicki, L. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina 2021, 57, 732. https://doi.org/10.3390/medicina57070732
Polewska K, Tylicki P, Biedunkiewicz B, Rucińska A, Szydłowska A, Kubanek A, Rosenberg I, Rodak S, Ślizień W, Renke M, Dębska-Ślizień A, Tylicki L. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina. 2021; 57(7):732. https://doi.org/10.3390/medicina57070732
Chicago/Turabian StylePolewska, Karolina, Piotr Tylicki, Bogdan Biedunkiewicz, Angelika Rucińska, Aleksandra Szydłowska, Alicja Kubanek, Iwona Rosenberg, Sylwia Rodak, Waldemar Ślizień, Marcin Renke, Alicja Dębska-Ślizień, and Leszek Tylicki. 2021. "Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project" Medicina 57, no. 7: 732. https://doi.org/10.3390/medicina57070732